Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced that it is collaborating with Moderna to support clinical trials of mRNA-1273, Moderna’s COVID-19 vaccine candidate.
Clinical-stage pharmaceutical company Humanetics has secured financing from the National Institute of Allergy and Infectious Diseases (NIAID) to carry out a test with its BIO 300 drug in Covid-19 patients.
XyloCor Therapeutics announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina.
AstraZeneca said that the AZD1222 vaccine candidate (formerly ChAdOx1 nCoV-19) licensed from the Oxford University has shown strong immune responses against the SARS-CoV-2 virus in all participants in a phase I/II trial.
ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study.
Chinese vaccine manufacturer Sinopharm CNBG has started a phase 3 trial of its Covid-19 inactivated vaccine candidate in the UAE.
Celltrion Group has commenced phase 1 human clinical study to assess the potential of its antiviral antibody treatment for patients with Covid-19.
Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17% (HR 0.83 [95% CI 0.71, 0.96], p=0.02), compared to aspirin alone in patients who had an acute ischemic stroke or transient ischemic attack (TIA).
BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for its Phase 2 Proof of Concept study of its lead product, recombinant human plasma gelsolin (rhu-pGSN) in hospitalized patients with severe COVID-19 pneumonia.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.